- Home
- CAQ vs FULC Comparison
CAQ vs FULC Comparison
Compare CAQ & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CAQ | FULC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.9M | 285.4M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CAQ | FULC |
|---|---|---|
| Price | $10.03 | $3.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $16.38 |
| AVG Volume (30 Days) | 104.1K | ★ 1.2M |
| Earning Date | N/A | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.90 | $2.83 |
| 52 Week High | $10.05 | $15.74 |
Technical Indicators
Market Signals| Indicator | CAQ | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 60.27 | 47.56 |
| Support Level | $9.97 | $3.62 |
| Resistance Level | $10.05 | $3.92 |
| Average True Range (ATR) | 0.01 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 73.75 | 27.27 |
Price Performance
Historical ComparisonAbout CAQ Cambridge Acquisition Corp. Class A Ordinary Shares
Cambridge Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.